PT - JOURNAL ARTICLE AU - S B Shah AU - R Chawla AU - A Pahade AU - N Bansal AU - A Mehta AU - A.K. Dewan AU - A Prakash AU - M Bhatia TI - Immunity status of Health Care Workers post recovery from COVID-19: An online longitudinal panel survey AID - 10.1101/2020.11.27.20239426 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.27.20239426 4099 - http://medrxiv.org/content/early/2020/11/30/2020.11.27.20239426.short 4100 - http://medrxiv.org/content/early/2020/11/30/2020.11.27.20239426.full AB - Background Corona virus has literally travelled “around the world in 80 days” akin to Fogg and Passepartoute of Jules Verne fame. Manning of corona virus disease 2019 (COVID-19) wards and ICUs, also surgery on COVID-positive patients is increasingly being relegated to that subset of health care workers (HCW) who themselves have resumed duties after surviving COVID-19 infection. Convalescent plasma therapy has been widely endorsed. Several vaccines are in the pipeline as potential preventive measures against the virus keeping HCW on the priority-list of recipients. Immunity passports are being validated for foreign travel. These events share a common presumption that exposure to COVID-19 virus (natural infection/inoculation) produces protective adaptive immunity. It is unknown whether all (COVID-19) infected patients mount a protective immune response and for how long any protective effect will last.Methods This single institutional prospective longitudinal panel survey questions were deployed to the respondents online via email/WhatsApp groups to ascertain the symptomology and immunity status of HCW in the months following COVID-19 infection. The survey was administered to the same set/cohort of health care workers over 6 months.Results 165 responses from 151 respondents (70 at 1-2months; 95 at 3-4 months including 14 at both time points) were analysed. 7.14% of infected HCW failed to develop IgG antibodies at 4-6 weeks. 91.7% HCW with IgG titres in the highest bracket had experienced anosmia. Mean antibody titres were 12.08 ± 9.56 and 9.72 ± 9.34 at 1-2 months and 3-4 months post-development of first symptom, respectively.Conclusion Understanding of COVID-19 patterns of variation in HCW may guide their deployment in the COVID ward and COVID-OTs. Revelation of this enigma (by quantification of serial IgG antibody levels) is critical for predicting response to vaccines under trial, fostering effective stratagems and tactics for pandemic control, ascertaining validity of immunity passports and understanding longevity/durability of protection by forecasting immunological memory against SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSources of funding/Financial disclosures: Upto 220 participants of the survey are entitled to subsidy on IgG antibody testing by the institution in which they are employed which is also the place of conduct of the survey( ie Rajiv Gandhi Cancer Institute and Research Centre; Sector -5; Rohini; Delhi-110085; India)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Rajiv Gandhi Cancer Institute and Research CentreAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is available